Brief summary: Direct drug administration through endoscopy opens new possibilities for therapeutic endoscopy in IBD. CoverGel is an endoscopic vehicle to locally deliver biological drugs with proven efficacy in acute and chronic experimental colitis in rats and inducing less immunogenicity reaction.
INTRODUCTION
Interventional inflammatory bowel disease (IBD) endoscopy has an expanding role in the era of biologic therapy. A significant number of patients have mucosal lesions refractory to biological treatments or have disease-associated adverse events that require surgical intervention such as strictures or neoplasia, despite the availability and growing use of anti-tumor necrosis factor (TNF), anti-integrin, anti-interleukin and new small-molecule 1,2 . These drugs have changed the way of treating IBD patients, but those situations represent unmet needs that require new treatment modalities to prolong the intervention-free period. Endoscopic shielding technique with hydrogels has been proposed by our group as a less invasive approach to reduce or postpone the need for surgical resection 3, 4 .
Hydrogels or hydrophilic gels are cross-linked polymeric three-dimensional networks which present soft tissue-like elastic, non-toxic and biodegradable properties while being responsive to stimulus [5] [6] [7] [8] .
C34H24N6Na4O14S4 and has a molar mass of approximately 960 Daltons (ii) Bovine serum albumin (BSA) which has a molecular weight of 66.5 kDa. For the Trypan blue experiments, first, a calibration curve was prepared by measuring the absorbance (λ=450 nm) of different concentrations of trypan blue diluted in water using a Uv-Vis spectrophotometer (Varioskan Flash, Thermo) SkanIt Software 2.4.1 was used to analyze results. Then, the curve equation was obtained:
y=6234.9x+0.1008. R² = 0.99349. Data not shown. Absorbance and release of BSA was evaluated with the Bicinchoninic acid (BCA) Protein Assay Kit (PierceTM, Thermo Scientific).
The BCA Protein Assay Kit is a colorimetric detection and quantification method of total protein.
It is based on the reduction of Cu+2 to Cu+1 by proteins in an alkaline medium (Biuret reaction) with the detection of cuprous cation (Cu+1) using BCA. The purple-colored reaction product of this assay is formed by the chelation of two molecules of BCA with one cuprous ion. Plates are then read at 562nm using a spectrophotometer. SkanIt Software 2.4.1 was used to analyze results.
To incorporate substances inside the hydrogel, 0.25 mL of gelated hydrogel were submerged in 5 mL of 0.0005 mg/mL Trypan Blue or 2 mg/mL BSA. Hydrogels incorporated the solution at room temperature for 48 hours. To calculate the amount of substance incorporated into the matrix of the hydrogel, the following equation was used: Incorporating efficiency (%):
. Where: V1: original volume of substance solution (mL). V2: remaining volume of substance X100 solution after 48h (mL). C1: initial concentration of substance (g/mL) and C2: remaining concentration of substance (g/mL).
Hydrogels were withdrawn from the solution and placed in release medium (PBS). At specific time points, amount of substance released into the medium was evaluated as mentioned before. The kinetics of drug release from the hydrogels was studied with three different models to asses which one fitted best with the release data from our experiments. The three different models were:
,
, and Higuchi release model: M t = K h t 1/2 Zero -order release model: M t = K 0 t . Where Mt is the fraction of drug released at each time First -order release model: M t = 1e -K 1 t point (t) and Kh, K0 and K1 are the Higuchi release kinetic constant, the zero-order release kinetic constant and the first-order release kinetic constant respectively.
Lastly, the drug release mechanism was analyzed using the Korsmeyer-Peppas model [F = (M t . This is a semi-empirical model used when the exact mechanism is not known or in /M) = K m t n ] the case that more than one mechanism is involved in the drug release. Where F is the fraction of drug released at time (t), Mt is the amount of drug released at time (t), M is the total amount of drug in the hydrogel, Km is a kinetic constant and n is the release exponent, indicative of the drug release mechanism. n is estimated from linear regression of log (Mt/M) versus log t; when determining the n exponent, only portions of the release curve 60% should be used. ≤ Biocompatibility assays (cytotoxicity, hemolysis and acute toxicity) were first performed to check the possible cytotoxicity induced by CoverGel, carrying out a co-culture of a cell line with different conditions involving our hydrogel. The cell line chosen for these experiments was Caco-2 (ATCC® HTB-37TM) a human colorectal adenocarcinoma cell line. For cytotoxicity evaluation, 3x104 cells/cm 2 cells were cultured in 24-well cell plates under the following conditions: Normal culture medium (DMEM medium supplemented with 10% Fetal Bovine serum, 1% L-Glutamine and 1% Penicillin/Streptomycin) as a positive control. Normal culture medium supplemented with 10%
Dimethyl sulfoxide (DMSO) as a negative control. Normal culture medium supplemented with 1%-2%-5%-10%-15% of hydrogel v/v. Cells were cultured at 37ºC and 5% CO 2 for 24, 48, 72 and 96 hours. At specific time points cell viability was evaluated using Resazurin Sodium Salt (Sigma-Aldrich). Resazurin sodium salt (7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt) is a blue dye weakly fluorescent until it is irreversibly reduced by living organism to Resofurin, a highly red fluorescent. The reduction of Resazurin Sodium Salt correlates with the number of living cells. Samples are exposed to Resazurin Sodium Salts for 4 hours and then absorbance at 570 nm is analyzed using a spectrophotometer (Varioskan Flash, Thermo).
Hemolysis test was done in vitro. Two mL of gelified hydrogel were placed in 20 mL of sterile saline and incubated for 72h at 37ºC. After, the solution was collected and filtered with a 0.22 µm membrane. Two mL blood samples were freshly collected from six male Sprague Dawley rats into an anticoagulant tube and gently mixed, blood was then diluted with 2.5 mL of saline. For the hemolysis test 10 mL of the hydrogel extraction, distilled water, and saline were poured in 50 mL test tubes and placed at 37ºC for 30 min. After that, 0.2 mL of diluted blood were added to each test tube with gently shaking and the solution was placed at 37ºC for 1 hour. The absorbance of the samples after 1 hour was evaluated with a spectrophotometer (Varioskan Flash, Thermo) at 545nm.
Chronic EC animal study
All animals included in this protocol underwent 4 rounds of TNBS colitis induction in the same fashion as the acute model, thus, induction was done on days 0, 7, 14 and 21, treatments were given on days 3, 10, 17 and 24 and euthanasia was performed on day 28. Twelve male Sprague Dawley rats were included. Animals were randomized in two groups: (i) IFX s.c. group: animals with EC treated with 5 mg/kg of IFX subcutaneously. (ii) CoverGel + IFX group: animals with EC treated with CoveGel+ IFX (1 mg/mL). All assessments were carried out the same way as in the acute EC study. Animals underwent endoscopic follow-up at days of induction, days of treatment and day of euthanasia. Furthermore, antibodies to IFX (ATIs) in serum were also evaluated. To separate ATIs from IFX as the might be found on blood, a protein G column and acidic buffer treatment were this intensity is measured by determining the optical density of each well using a microplate reader at 450 nm with a wavelength correction set to 540 nm using a spectrophotometer (Varioskan Flash, Thermo). SkanIt Software 2.4.1 was used to analyze results.
Statistical study
All values are expressed in median  range unless otherwise stated. Comparison of groups was done using 2 ways ANOVA and Tuckey's multiple comparison tests as a posthoc. Release kinetics was studied using mean values of 6 different experiments and a nonlinear regression fit to each different model equation. Graphpad Prism 6.0 software was used to perform analysis.
RESULTS

Development of the drug-eluting platform
All hydrogels showed a similar adhesion force at 22ºC, but when temperature was raised, adhesion force of only CD2 (CoverGel) was highly increased, from -25 to -3993 mN/s ( Figure 1A ). Viscosity () of all samples was similar at 22C, but when temperature was increased to 37C, viscosity of CD2 was increased from <1 Pas at 22 ºC to 1500 Pas at 37 ºC ( Figure 1B ). In addition, the morphology of irreversible hydrogel was evaluated by SEM observing that it is formed by a structured network with well-defined porous distribution ranging from 50-300 m ( Figure 1C ).
Reversible and irreversible gelation of the hydrogel was acquired. Hydrogel can be given smoothly through a catheter (diameter 2.0-2.2 mm) by applying a force of 370 mmHg (0.48 atmospheres).
Hydrogel was also stable during 30 days at physiological-like conditions (Figure 2A) Figure 2B ). Table 2 shows correlation coefficient of the different kinetic models and the Korsmeyer-Peppas mechanism model.
CoverGel showed good biocompatibility, both in vitro and in vivo studies. Caco-2 cells cultured with different concentrations of our hydrogel showed an increased proliferation, reaching a top at 10% when compared to the positive control of the experiment (normal culture medium) ( Figure 3 ).
Hemolysis rate caused by our hydrogel on blood from three different rats was 2.829  1.135%.
There was no sign of inflammation, toxicity or tissue malformation on major organs induced by the hydrogel. Macroscopic evaluation of major organs didn't show any signs of abnormalities, and organs weight with respect of total body mass didn't present any significant differences ( Figure 4A ).
Heart tissue didn't show signs of toxicity, cardiac myocytes maintain a good arrangement, and no hemorrhage, inflammation nor necrosis is observed. In the liver, no hepatocellular degeneration occurs, and there isn't an abnormal neutrophil, lymphocyte or macrophage infiltrate in the tissue.
Tissue structure from spleen, kidneys and lungs is maintained as well ( Figure 4B ). Subcutaneous placement of 0.5g of the hydrogel showed a synovial metaplasia, a capsular surface covered by fibrohistiocytic cells that are grouped forming pseudovilli. No toxicity or inflammation was seen in the surrounding tissue, meaning that the body responded by encapsulating the hydrogel as it would do with a foreign body, but no rejection response was triggered ( Figure 4C ). At the time of placement, hydrogels weighted 0.5 g; when extracted, the weight was 0.95  0.06 g. The platform was able to maintain its porosity and inner structure. No cell infiltration was seen 10 days after subcutaneous placement. ( Figure 4D ).
Efficacy of the drug-eluting platform in acute EC animal study
At day 3 all animals presented an entire circumferential affectation of the wall. Macroscopic and endoscopic evaluations at day 7, showed a complete mucosal restoration (vascular pattern, ulceration and friability) in CoverGel+IFX and CoverGel+VDZ groups, whereas in CoverGel group, this mucosal restoration was not complete. However, all treated groups clearly showed less mucosal damage than Control group ( Figure 5 ). All animals with acute EC had lost more than 8%
of original weight at day 3. At day 7 control animals showed a significantly weight loss (-55%), which confirm severe disease, as compared with the other groups. Drug-eluting platform with IFX or VDZ showed a significantly weight recovery in comparison with CoverGel without bioactive drug (-17% and -20% vs. -36%; p<0.044) ( Figure 6A ).
BT to liver at day 7 was absent in sham animals. Control group presented a significantly higher BT as compared with CoverGel+IFX and CoverGel+VDZ (100% vs. 14.3% and 16.6%; p<0.05).
Animals treated with CoverGel showed a decreased BT (62.5%) without statistical differences ( Figure 6B ). Histological score for groups with EC was comparable: Figure 6D ).
Chronic EC animal study
There was variation in both groups in the degree of colitis induction throughout the 4 TNBS applications. Figure 7 shows representative endoscopic and macroscopic images of both groups, showing ulcerated mucosa covered by feces despite lavages. No statistically significant differences were observed in ponderal evolution at any day of the study ( Figure 8A ), in BT to liver (two animals out of six in each group, 33.3%) ( Figure 8B ) and in histological score for CoverGel+IFX Figure 8D ).
The evolution of levels of ATIs for each group is shown in Figure 9 . At day of euthanasia, levels of ATIs were significantly lower in rats treated with CoverGel+IFX compared to rats treated with IFX subcutaneously (0.90  0.06 g/mL-c vs. 1.97  0.66 g/mL-c, p=0.0025).
DISCUSSION
Mucosal lesions refractory to biological treatments in IBD patients is a clinical challenge and unmet need that requires new treatment modalities. Drug delivery directly to the colon is an option thanks to oral dosage formulations that are designed to achieve a controlled drug release. However, this controlled release has mainly been achieved with small molecules but not for macromolecules, such as biologics 10 . Direct release in the colon is beneficial to prevent early absorption of the drug, thus increasing the quantity of drug reaching the target tissue and at the same time decreasing systemic exposure and associated side effect. A specific form of control drug release is polymer-based drug delivery. Polymers offer a wide range of possibilities useful for colonic delivery. These polymers can be triggered to start releasing drug by physiological characteristics of the healthy colon, as well as in different disease situations 10 . Hydrogels for drug delivery have also been studied for their capacity of mucoadhesion and controlled delivery 11 .
Local injection of infliximab can be a novel scenario for endoscopic therapy in IBD patients with symptomatic isolated mucosal lesions, as has been proposed by our group 12 . The real efficacy of locally injected IFX is not discernible from current literature, but available data seem encouraging at dose of 100 mg per session, assuming that higher anti-TNF concentrations given through local injection can favor healing and prevent adverse events, because a trend for a dose-response curve was observed. Topical injection of anti-TNF agents has been described in the treatment of longstanding perianal fistulizing CD in the absence of abscess 2 . There are technical variations in topical injection of the anti-TNF agents. The agents were injected in a circumferential or intrafistula fashion via the external or internal.
In this work we have provided new therapeutic tool for endoscopy by developing a new hydrogel (CoverGel) based on HA, MC and F127 which presents biocompatible, bioadhesive and bioactive properties [13] [14] [15] [16] [17] . CoverGel is an endoscopic vehicle to locally deliver biological drugs (IFX and VDZ) with proven efficacy in acute and chronic EC in rats. Moreover, endoscopic administration of IFX induces significantly lower levels of ATI as compared with subcutaneous administration.
The rationale for the drugs dosages used (1 mg/mL) with our drug eluting gel are based on previous clinical experience with local injection of IFX 12 .
Our developed hydrogel showed a reverse thermo sensitive capacity of gelation accompanied by a greater adhesion capacity. When the hydrogel contacts the mucosal layer at a physiological temperature, it gellifies permitting the adhesion to the mucosa 18 . Rheological studies in our hydrogel confirmed that it is a non-Newtonian fluid, meaning that its viscosity varies with temperature. Morphologically, our hydrogel presents a macroporous (pore diameters of greater than 50 nm) interconnected network that can be the matrix for cell ingrowth as well as nutrients and waste flow, essential characteristics for cell survival within the hydrogel. This platform is less vulnerable to matrix transformations due to osmotic pressure or tissue extrusion, which is an advantage for a controlled drug release of the hydrogel 19 . Different kinetic models were studied with the results obtained from the drug release experiments. The kinetic model that best fitted our results was the Higuchi release model. This model is explained by Fick´s law, in which diffusion of a molecule is related to its concentration. The diffusion flux goes from a higher concentrated area to a lesser-concentrated one. The magnitude of the diffusion flux will be proportional to the concentration gradient. These results and kinetic model were confirmed when mechanistic of drug release from Covergel were studied by the Korsmeyer-Peppas model, confirming that the diffusion coefficient follows a Fickian diffusion. Our hydrogel showed the capacity to improve cellular viability in a dose-dependent manner at least until a 10%, demonstrating a good potential to become a cell carrier. Intraperitoneal injection stated that CoverGel did not cause an acute toxicity reaction on animals three or seven days post intraperitoneal injection. Subcutaneous placement of our hydrogel in rats was done to evaluate in vivo behavior and biodegradability of our hydrogel, which was evaluated by SEM and we confirmed that the inner structure was maintained 10 days after s.c. placement and no cell infiltration were seen.
All of these results help us conclude that this hydrogel is a good candidate to be used in the digestive system and implement it in endoscopic techniques in order to cover some unmet needs of the field. Although in vitro and in vivo results are really promising, further experiments on in vivo drug release kinetics and degradation need to be performed, as these characteristics have previously been reported to vary from in vitro analysis to in vivo, due to inflammatory cell response [20] [21] [22] .
TNBS induces colitis has been proven as a valid method to elucidate different mechanisms underlying the mechanism of the disease 23 . Furthermore, and besides its limitations mimicking population refractory to biological treatments, this model is a great tool to study the immunopathogenesis of the disease and the potential benefit of different therapies 23 .
Our results show that the simple application of our hydrogel as a dressing on the inflamed tissue by means of a shield to improves the overall outcome and restoration of the mucosal layer. This beneficial effect of CoverGel is based on its good biocompatibility properties, able to improve mucosal healing. However, when CoverGel is loaded with biological drugs with proven efficacy treating this disease, the effect is even more pronounced. In this sense, endoscopic response was 
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